Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 113 Results

Title
Intervention Indication Therapeutic Area Year Actions
Encorafenib with binimetinib for treating metastatic BRAF V600 mutant non-small-cell lung cancer Binimetinib (MEK162; MEK-162; ARRY-162) , Encorafenib (LGX818) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Encorafenib with binimetinib for treating metastatic BRAF V600E mutant non-small-cell lung cancer Binimetinib (MEK162; MEK-162; ARRY-162) , Encorafenib (LGX818) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Entrectinib for ROS1 fusion positive, locally advanced or metastatic non-small cell lung cancer Entrectinib (RXDX-101) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR-mutated locally advanced or metastatic non-small-cell lung cancer after osimertinib failure Amivantamab (JNJ-6372; JNJ-61186372) , Lazertinib , Platinum-based chemotherapy Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Lenvatinib with pembrolizumab for previously treated metastatic non-small cell lung cancer Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Listeria monocytogenes vaccine for unresectable malignant plural mesothelioma CRS-207 Malignant pleural mesothelioma (MPM) Lung and Respiratory Cancer 2017 View  |  Download
Lorlatinib (PF-06463922) for advanced ALK or ROS1 positive non-small cell lung cancer – second line Lorlatinib (PF-06463922; Lorviqua) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Lorlatinib for advanced ALK-positive non-small cell lung cancer – first line Lorlatinib (PF-06463922; Lorviqua) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Lurbinectedin in addition to doxorubicin for small-cell lung cancer after prior platinum-containing therapy Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) , Lurbinectedin (PM01183; Zepzelca) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2020 View  |  Download
Lurbinectedin with atezolizumab maintenance therapy for extensive-stage small-cell lung cancer Atezolizumab (Tecentriq; MPDL3280A) , Lurbinectedin (PM01183; Zepzelca) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications